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Simvastatin Attenuates the Activity of Matrix Metalloprotease-9
in Aneurysmal Aortic Tissue
J. Evans,1* J.T. Powell,2 E. Schwalbe,1 I.M. Loftus3 and M.M. Thompson3
1Department of Surgery, University Hospitals of Leicester, UK, 2Department of Surgery, Imperial School
of Medicine, UK, and 3Department of Surgery, St George’s Hospital Medical School, London, UK
To investigate whether statins reduce the concentration of MMP-9 in the aortic wall, we randomised patients undergoing
elective open repair of an abdominal aortic aneurysm (AAA) to a pre-operative course of either simvastatin or placebo.
MMPs in aortic biopsies were measured using gelatin zymography.
Although recruitment closed early because of increasing statin use among eligible patients, with only 21 patients we
demonstrated a 40% reduction in MMP-9 levels in the AAA wall in patients randomised to simvastatin. This provides
a possible molecular mechanism to explain the reportedly beneficial effects of statins to slow AAA growth.
 2007 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Increasing understanding about the pathogenesis of
abdominal aortic aneurysm (AAA) development has
generated hope that pharmacotherapy can be targeted
to patients with small aneurysms to prevent growth.
HMG CoA Reductase inhibitors (statins) are of par-
ticular interest, since they may limit AAA growth,1,2
possibly through inhibitory action towards MMP
activity3 and production4 in the aortic wall.
To test this hypothesis, we randomised patients
scheduled for elective open AAA repair to a pre-
operative course of either simvastatin or placebo and
measuredMMP-9 concentration in aneurysm biopsies.
Experimental Design
All patients with large AAAwere eligible for random-
isation to receive either simvastatin 40 mg or placebo
(Merck Sharpe and Dohme, Hoddesdon, UK) once
daily for 3 weeks prior to elective aneurysm surgery.
Patients already taking a statin and those unable to
give informed consent were excluded from the trial.
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ration of Helsinki and ethical approval was granted
by the local ethics board with written consent from
each patient.
Consecutive sealed envelopes, containing allocation
to simvastatin or identical placebo were opened by
a third-party at the randomisation centre: compliance
was monitored by tablet counts. Intra-operatively,
a section of anterior aneurysm wall was excised and
transported to the laboratory in tissue culture medium
for immediate processing, with MMP-9 (and MMP-2)
in homogenates measured by zymography.5
The principal outcome measure was the reduction
in total MMP-9 (by activity) in homogenates of fresh
aortic wall. In order to observe w30% reduction
from a mean of 1.4 (sd 0.6) to 1.0 (sd 0.6) densitometric
units associated with simvastatin treatment with 90%
power and 5% significance, a total of 96 patients
would be required, 48 in each arm.
Mann Whitney tests with regression analysis to ad-
just for age, sex and diabetes were used for statistical
analysis with results reported as mean sd.
Results
Of 32 patients eligible for the trial, one refused ran-
domisation. During the latter half of recruitment mostar Surgery. Published by Elsevier Ltd. All rights reserved.
303Simvastatin Reduces MMP-9 in Aortic Aneurysmspatientswere current statin users (n¼ 10) and therefore
the trial closed early after 10 patients had been rando-
mised to simvastatin and 11 to placebo (demographic
features by randomised group in Table 1). One patient
developed renal failure and was withdrawn from the
study, and aneurysm sac was unavailable in three
others for technical reasons.
The total activity, in aneurysm wall excised at sur-
gery, of MMP-9 (pro and active forms) was lower in
the simvastatin group (unadjusted p¼ 0.015, adjusted
p¼ 0.032), Table 2. Active MMP-2 levels varied
widely, although total MMP-2 was non-significantly
lower in the simvastatin group.
Discussion
During the recruitment period the published evidence
for the beneficial effects of statins in vascular patients,
irrespective of their lipid indicators, became over-
whelming. Therefore, after the first year, the majority
of patients considered for recruitment were ineligible
due to current statin use. However, despite recruiting
only a quarter of the numbers suggested by the power
calculation, a 40% reduction in total MMP-9 concen-
tration in the aortic wall was observed in patients
randomised to simvastatin.
Therefore, our study suggests that one of the mech-
anisms underlying the beneficial effects of statins in
patients with AAA is a reduction in MMP-9 content
and activity in the aneurysm wall. Since MMP-9 has
been considered a pivotal enzyme in AAA develop-
ment and expansion, our findings could provide a
molecular basis for the prliminary observations that
statin therapy is associated with reduced AAA
growth rate in man.
Patients with abdominal aortic aneurysm have in-
creased cardiovascular mortality and there are many
Table 1. Demographics of randomised patients
Placebo
N¼ 11
Simvastatin
N¼ 10
Age (Mean SD) 74 4.6 72 7.46
Male/female 7/3 11/0
Current smokers 6 5
Diabetes 1 1
History of hypertension 5 2
Aortic diameter (Mean SD) 6.0 0.97 6.4 0.60reasons to recommend that all patients with AAA re-
ceive statin therapy. Which statin and at what dosage
would have most beneficial effect on AAA growth
remains to be elucidated.
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Table 2. The effect of pre-operative simvastatin on MMP-2 and
MMP-9 in aortic wall
Placebo
(n¼ 10)
Simvastatin
(n¼ 7)
P-value Adjusted
p value*
Pro MMP-9 0.70 0.49 0.33 0.12 0.063 0.154
Active MMP-9 1.18 0.52 0.75 0.28 0.040 0.156
Total MMP-9 1.75 0.74 1.01 0.38 0.015 0.032
Pro MMP-2 1.12 0.77 0.65 0.28 0.045 0.151
Active MMP-2 10.1 10.7 10.3 10.3 0.769 0.327
Total MMP-2 11.3 10.4 10.9 10.1 0.381 0.285
Results are given as mean sd.
* Adjusted for age, sex and diabetes.Eur J Vasc Endovasc Surg Vol 34, September 2007
